Terms: = Cervical cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
94 results:
1. MRI Plain Scan: A Tool in the Management of cervical cancer during Pregnancy.
Gao F; Qian T; Sun M; Lu Y; Cheng J; Fu L
Curr Med Imaging; 2024; 20():1-8. PubMed ID: 38389369
[TBL] [Abstract] [Full Text] [Related]
2. Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line treatment in Recurrent or Metastatic cervical cancer (COMPASSION-13): A Phase 2 Study.
Lou H; Cai H; Huang X; Li G; Wang L; Liu F; Qin W; Liu T; Liu W; Wang ZM; Li B; Xia Y; Wang J
Clin Cancer Res; 2024 Apr; 30(8):1501-1508. PubMed ID: 38372727
[TBL] [Abstract] [Full Text] [Related]
3. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
4. Safety and antitumour activity of cadonilimab, an anti-PD-1/ctla-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Gao X; Xu N; Li Z; Shen L; Ji K; Zheng Z; Liu D; Lou H; Bai L; Liu T; Li Y; Li Y; Fan Q; Feng M; Zhong H; Huang Y; Lou G; Wang J; Lin X; Chen Y; An R; Li C; Zhou Q; Huang X; Guo Z; Wang S; Li G; Fei J; Zhu L; Zhu H; Li X; Li F; Liao S; Min Q; Tang L; Shan F; Gong J; Gao Y; Zhou J; Lu Z; Li X; Li J; Ren H; Liu X; Yang H; Li W; Song W; Wang ZM; Li B; Xia M; Wu X; Ji J
Lancet Oncol; 2023 Oct; 24(10):1134-1146. PubMed ID: 37797632
[TBL] [Abstract] [Full Text] [Related]
5. Pathogenomics model for personalized medicine in cervical cancer: Cross-talk of gene expressions and pathological images related to oxidative stress.
Li J; Chen S; Wu J; Liu X; Liu H; Liu Y; Zhu Z
Environ Toxicol; 2024 Feb; 39(2):751-767. PubMed ID: 37755325
[TBL] [Abstract] [Full Text] [Related]
6. Handheld vital microscopy for the identification of microcirculatory alterations in cervical intraepithelial neoplasia and cervical cancer.
Latul YP; Ince C; van Trommel NE; van den Brandhof-van den Berg A; Roovers JPWR; Kastelein AW
Microvasc Res; 2024 Jan; 151():104608. PubMed ID: 37690508
[TBL] [Abstract] [Full Text] [Related]
7. The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge.
Li C; Cang W; Gu Y; Chen L; Xiang Y
Front Immunol; 2023; 14():1195476. PubMed ID: 37559727
[TBL] [Abstract] [Full Text] [Related]
8. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/ctla4 dual blocker, in patients with advanced solid tumors.
Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
[TBL] [Abstract] [Full Text] [Related]
9. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.
Wang Y; Mao Y; Wang C; Jiang X; Tang Q; Wang L; Zhu J; Zhao M
Ann Med; 2023 Dec; 55(1):2190618. PubMed ID: 37042849
[TBL] [Abstract] [Full Text] [Related]
10. Signatures of immune cell infiltration for predicting immune escape and immunotherapy in cervical cancer.
Chen F; Shen L; Wang Y; Chen Y; Pan X; Liang H; Yu H
Aging (Albany NY); 2023 Mar; 15(5):1685-1698. PubMed ID: 36917087
[TBL] [Abstract] [Full Text] [Related]
11. Dynamics in the expression of programmed death ligand 1 and cluster of differentiation 163 in the tumor microenvironment of uterine cervical cancer: a single-center retrospective study.
Miyata Y; Ogo E; Abe T; Hirata H; Tsuda N; Ushijima K; Kawahara A; Akiba J; Obara H; Kakuma T
Radiat Oncol; 2023 Feb; 18(1):40. PubMed ID: 36823665
[TBL] [Abstract] [Full Text] [Related]
12. Application of Immune Checkpoint Inhibitors in Gynecological cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?
Lee SM; Lee S; Cho HW; Min KJ; Hong JH; Song JY; Lee JK; Lee NW
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674491
[TBL] [Abstract] [Full Text] [Related]
13. Laparoscopic Radical Hysterectomy Combined with Neoadjuvant Chemotherapy for cervical cancer Patients Effectively Improves Immune Function.
Liu M; Wang H; Du S; Li W; Xuan F; Zhao Y; Li N
Dis Markers; 2022; 2022():3611174. PubMed ID: 36157208
[TBL] [Abstract] [Full Text] [Related]
14. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in cervical cancer.
Ge Y; Zhang Y; Zhao KN; Zhu H
Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
[TBL] [Abstract] [Full Text] [Related]
15. Single-cell RNA-sequencing dissects cellular heterogeneity and identifies two tumor-suppressing immune cell subclusters in HPV-related cervical adenosquamous carcinoma.
Li X; Zhang M; Lei T; Zou W; Huang R; Wang F; Huang Q; Wang C; Liu C
J Med Virol; 2022 Dec; 94(12):6047-6059. PubMed ID: 36000446
[TBL] [Abstract] [Full Text] [Related]
16. Cadonilimab: First Approval.
Keam SJ
Drugs; 2022 Aug; 82(12):1333-1339. PubMed ID: 35986837
[TBL] [Abstract] [Full Text] [Related]
17. Comparative Analysis of the Antitumor Immune Profiles of Paired Radiotherapy-naive and Radiotherapy-treated cervical cancer Tissues.
Imamura A; Oike T; Sato H; Yoshimoto Y; Ando K; Ohno T
Anticancer Res; 2022 Jul; 42(7):3341-3348. PubMed ID: 35790266
[TBL] [Abstract] [Full Text] [Related]
18. Immune checkpoint blockades in gynecological cancers: A review of clinical trials.
Peng H; He X; Wang Q
Acta Obstet Gynecol Scand; 2022 Sep; 101(9):941-951. PubMed ID: 35751489
[TBL] [Abstract] [Full Text] [Related]
19. Long-term quality of life assessment after excisional treatment for cervical dysplasia.
Sparić R; Bukumirić Z; Stefanović R; Tinelli A; Kostov S; Watrowski R
J Obstet Gynaecol; 2022 Oct; 42(7):3061-3066. PubMed ID: 35695230
[TBL] [Abstract] [Full Text] [Related]
20. Current and emerging immunotherapies for recurrent cervical cancer.
Liu MC; Tewari KS
Clin Adv Hematol Oncol; 2022 Feb; 20(2):108-115. PubMed ID: 35120091
[TBL] [Abstract] [Full Text] [Related]
[Next]
